Evidence map›Paper›PMID 21963870›Full record

ArticleVaccine2011

Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

Kae Pusic, Hengyi Xu, Andrew Stridiron, Zoraida Aguilar, Andrew Wang, George Hui

Abstract read
In one paragraph

Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kae PusicUniversity of Hawaii, School of Medicine, Department of Tropical Medicine, 651 Ilalo Street, BSB320 Honolulu, HI 96813, USA.
Hengyi Xu
Andrew Stridiron
Zoraida Aguilar
Andrew Wang
George Hui
Ocean NanoTech (United States) · USUniversity of Hawaii System · US

Funding

UHI COBRE: P3: GROUP A STREPT IN RELATION TO ACUTE RHEUMATIC FEVER IN HAWAIIP20RR018727 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI HOANG, TUNG T · 2003 to 2011
$13.8M
Pacific High Schools STEP-UP to One HealthR25DK078386 · NIDDK · UNIVERSITY OF HAWAII AT MANOA · PI George S Hui · 2007 to 2026
$5.3M
Novel Engineering of a P. falciparum Merozoite Surface Protein 1 Malaria VaccineR21AI076955 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI HUI, GEORGE S · 2008 to 2010
$514k
NCRR NIH HHS 5P20RR018727-07NCRR NIH HHS P20 RR018727NIAID NIH HHS R21 AI076955NIDDK NIH HHS DK078386NIDDK NIH HHS R25 DK078386PHS HHS A1076955
6 · The paper itself

Abstract

In this proof-of-concept study we report the use of <15 nm, water soluble, inorganic nanoparticles as a vaccine delivery system for a blood stage malaria vaccine. The recombinant malarial antigen, Merozoite Surface Protein 1 (rMSP1) of Plasmodium falciparum served as the model vaccine. The rMSP1 was covalently conjugated to polymer-coated quantum dot CdSe/ZnS nanoparticles (QDs) via surface carboxyl groups, forming rMSP1-QDs. Anti-MSP1 antibody responses induced by rMSP1-QDs were found to have 2-3 log higher titers than those obtained with rMSP1 administered with the conventional adjuvants, Montanide ISA51 and CFA. Moreover, the immune responsiveness and the induction of parasite inhibitory antibodies were significantly superior in mice injected with rMSP1-QDs. The rMSP1-QDs delivered via intra-peritoneal (i.p.), intra-muscular (i.m.), and subcutaneous (s.c.) routes were equally efficacious. The high level of immunogenicity exhibited by the rMSP1-QDs was achieved without further addition of other adjuvant components. Bone marrow derived dendritic cells were shown to efficiently take up the nanoparticles leading to their activation and the expression/secretion of key cytokines, suggesting that this may be a mode of action for the enhanced immunogenicity. This study provides promising results for the use of water soluble, inorganic nanoparticles (<15 nm) as potent vehicles/platforms to enhance the immunogenicity of polypeptide antigens in adjuvant-free immunizations.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ProtozoanCytokinesDendritic CellsFemaleImmunoglobulin GMalaria, FalciparumMalaria VaccinesMerozoite Surface Protein 1MiceMice, Inbred C57BLNanoparticlesPlasmodium falciparumQuantum DotsRecombinant ProteinsAdjuvants, ImmunologicAntibodies, ProtozoanCytokinesImmunoglobulin GMalaria VaccinesMerozoite Surface Protein 1Recombinant Proteins

Identifiers

PMID21963870
PMCPMC3202662
OpenAlexW2094561249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.